Royal Bank of Canada (RY) is offering principal-protected-conditional notes linked to the MSCI EAFE Index with a $1,000 denomination. These notes have a 15% downside buffer and offer a 160% upside participation rate, capped at an expected maximum settlement between $1,285.92 and $1,336.32 per $1,000. Investors risk losing their entire principal if the final index level falls below the 85% buffer.

Goldman Sachs' investment banking and trading strengths are crucial for its resilience amidst market volatility, making it a key player for investors seeking stability. The firm's business model, which focuses on high-margin institutional services and advisory roles in complex deals, positions it to capture significant fees even during choppy markets. With a strategic pivot towards its core franchises and a competitive edge over rivals, Goldman Sachs remains a significant indicator of global deal activity and financial health for investors.

Potomac Edison, a subsidiary of FirstEnergy Corp., has introduced a new residential time-of-use rate in Maryland, allowing customers to save on their electric bills by shifting electricity consumption to off-peak hours. This rate offers lower prices during mornings, late evenings, and weekends, compared to higher weekday peak hours. Customers can enroll by calling 1-800-686-0011 and need to have their electricity supply through Potomac Edison.

Venezuela's interim president, Delcy Rodríguez, announced that her government is in talks with Siemens and General Electric to address the country's power crisis, particularly in the oil-producing Zulia state. This diplomatic engagement follows a recent U.S. military operation and efforts by both companies to assess Venezuela's electrical infrastructure. Rodríguez also launched a pilgrimage to demand the full lifting of economic sanctions, which she claims have worsened the crisis.

Dollar General (DG) stock experienced a 1.05% decline following news that Hudson Edge Investment Partners reduced its holdings by 13.4% in Q4. Despite trading above its short-term and long-term moving averages, the stock remains below its medium-term average and faces persistent selling pressure and market headwinds. Analysts suggest a bearish outlook, with limited chances for an upward move and a critical support level around $121 to watch.

CMS Energy (NYSE: CMS) has declared a quarterly common-stock dividend of $0.57 per share, payable on May 29, 2026, to shareholders of record as of May 8, 2026. This announcement confirms the continuation of the dividend rate set in February 2026 and aligns with the company's consistent pattern of shareholder-return oriented dividend trajectory. Historically, similar dividend announcements have led to modestly positive next-day stock movements for CMS.

CMS Energy's Board of Directors has declared a quarterly dividend of 57 cents per share on the company's common stock (CUSIP: 125896100). The dividend is payable on May 29, 2026, to shareholders of record as of May 8, 2026. Further tax information regarding the dividend distributions is available on the company's website, www.cmsenergy.com.

The Hartford Insurance Group, Inc. (HIG) is expected to report its first-quarter 2026 earnings on April 23, with analysts projecting a significant year-over-year increase in EPS. The company shows a strong likelihood of surpassing estimates, driven by anticipated improvements in Personal and Business Insurance combined ratios and pre-tax income. Zacks Investment Research highlights HIG's positive Earnings ESP and favorable Zacks Rank, suggesting a potential earnings beat.

Enveric Biosciences (ENVB) stock surged 134.4% following the announcement of its at-the-market private placement closing. This includes a substantial warrant package, which likely contributed to increased trading interest, short-covering, and momentum buying in the small-cap biotech. The private placement secured $5.0 million upfront, with potential for an additional $8.9 million if warrants are fully exercised.

Jefferies has reiterated a Buy rating on Erasca Inc (NASDAQ:ERAS) with a $21.00 price target, anticipating that the upcoming ASCO 2026 conference will be a significant inflection point for the stock. The firm expects initial phase I monotherapy data for ERAS-0015 to be presented, potentially demonstrating competitive efficacy and a better safety profile compared to existing treatments. Despite the stock appearing overvalued according to InvestingPro analysis, Jefferies believes even modest positive early separation could lead to a favorable stock reaction given Revolution Medicines' high valuation in takeover discussions.